Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Persistent Losses NRIX has ample liquidity and low leverage, but severe losses, rapid cash burn, minimal revenue, and a high valuation make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Weakening momentum ⢠Key support test ⢠Breakout threshold Support Level: $25.30â$25.50 Resistance Level: $26.90â$27.10 NRIX is mildly bearish over the last month, trading below its 21-day average with weakening momentum; watch $25.30 support and reclaiming $26.50â$27.10 for a bullish reversal.
Sentiment & News
Key News Insights: ⢠Roche Partnership ⢠Extended Runway ⢠Phase 3 Plans Nurix's Roche deal materially strengthens its cash runway, reduces dilution risk, and supports bexobrutideg's Phase 3 path, reinforcing bullish momentum.
AI Summary
Roche's $700M upfront payment and shared Phase 3 development transform NRIX from a near-term financing-risk biotech into a well-funded, partner-validated bexobrutideg story, but the premium valuation now hinges on proving early CLL/SLL results can outperform pirtobrutinib in pivotal trials. Investors should view the stock as attractive only if they can tolerate binary clinical risk and avoid underwriting contingent milestones as current value.
Description
Nurix Therapeutics is a biopharmaceutical company that discovers and develops small-molecule treatments for oncology and immune disorders, with an emphasis on orally administered BTK degraders and CBLâB modulators. Its pipeline includes agents for relapsed or refractory Bâcell malignancies, therapies to support adoptive Tâcell approaches, and a cell therapy candidate in Phase 1 for gynecologic cancers. The company collaborates with Gilead and Sanofi, was incorporated in 2009, and is headquartered in San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 15 | Jul 22 | NRIX | Nurix Therapeutics, Inc. | Speculative but catalyst-rich biotech setup: Roche collaboration brought $700M upfront and up to $2.3B in potential payments, while NX-5948 Phase 1a/b data showed 92.9% ORR in second-line post-BTK CLL/SLL patients. Shares are up about 38% over the last 20 trading days, supported by a stronger biotech tape. | Closed | -1.1% |
| Jul 2 | Jul 9 | NRIX | Nurix Therapeutics, Inc. | Strong near-term catalyst and momentum setup: stock rose about 42% over 21 trading days, supported by Roche collaboration worth up to $2.3B with $700M upfront and positive NX-5948 CLL/SLL data including 92.9% ORR in a second-line group. | Closed | +3.0% |